A 64-year-old man with long-standing type 2 diabetes and obesity is reviewed in clinic. His HbA1c remains 76 mmol/mol despite maximal tolerated Metfor...

Question

A 64-year-old man with long-standing type 2 diabetes and obesity is reviewed in clinic. His HbA1c remains 76 mmol/mol despite maximal tolerated Metformin. According to current NICE guidance, which class of drug is now recommended as first-line add-on with evidence of cardiovascular benefit?

Accepted Answer

SGLT2 inhibitor (e.g. Empagliflozin)

Answer

Sulfonylurea (e.g. Gliclazide)

Answer

DPP-4 inhibitor (e.g. Sitagliptin)

Answer

Basal insulin

Answer

Thiazolidinedione (e.g. Pioglitazone)

uk-plab-1 MCQ (SBA): Type 2 diabetes management

A 64-year-old man with long-standing type 2 diabetes and obesity is reviewed in clinic. His HbA1c remains 76 mmol/mol despite maximal tolerated Metformin. According to current NICE guidance, which class of drug is now recommended as first-line add-on with evidence of cardiovascular benefit?